Cargando…

Development of a Nuclear Morphometric Signature for Prostate Cancer Risk in Negative Biopsies

BACKGROUND: Our objective was to develop and validate a multi-feature nuclear score based on image analysis of direct DNA staining, and to test its association with field effects and subsequent detection of prostate cancer (PCa) in benign biopsies. METHODS: Tissue sections from 39 prostatectomies we...

Descripción completa

Detalles Bibliográficos
Autores principales: Gann, Peter H., Deaton, Ryan, Amatya, Anup, Mohnani, Mahesh, Rueter, Erika Enk, Yang, Yirong, Ananthanarayanan, Viju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724855/
https://www.ncbi.nlm.nih.gov/pubmed/23922715
http://dx.doi.org/10.1371/journal.pone.0069457
_version_ 1782476736488800256
author Gann, Peter H.
Deaton, Ryan
Amatya, Anup
Mohnani, Mahesh
Rueter, Erika Enk
Yang, Yirong
Ananthanarayanan, Viju
author_facet Gann, Peter H.
Deaton, Ryan
Amatya, Anup
Mohnani, Mahesh
Rueter, Erika Enk
Yang, Yirong
Ananthanarayanan, Viju
author_sort Gann, Peter H.
collection PubMed
description BACKGROUND: Our objective was to develop and validate a multi-feature nuclear score based on image analysis of direct DNA staining, and to test its association with field effects and subsequent detection of prostate cancer (PCa) in benign biopsies. METHODS: Tissue sections from 39 prostatectomies were Feulgen-stained and digitally scanned (400×), providing maps of DNA content per pixel. PCa and benign epithelial nuclei were randomly selected for measurement of 52 basic morphometric features. Logistic regression models discriminating benign from PCa nuclei, and benign from malignant nuclear populations, were built and cross-validated by AUC analysis. Nuclear populations were randomly collected <1 mm or >5 mm from cancer foci, and from cancer-free prostates, HGPIN, and PCa Gleason grade 3–5. Nuclei also were collected from negative biopsy subjects who had a subsequent diagnosis of PCa and age-matched cancer-free controls (20 pairs). RESULTS: A multi-feature nuclear score discriminated cancer from benign cell populations with AUCs of 0.91 and 0.79, respectively, in training and validation sets of patients. In prostatectomy samples, both nuclear- and population-level models revealed cancer-like features in benign nuclei adjacent to PCa, compared to nuclei that were more distant or from PCa-free glands. In negative biopsies, a validated model with 5 variance features yielded significantly higher scores in cases than controls (P = 0.026). CONCLUSIONS: A multifeature nuclear morphometric score, obtained by automated digital analysis, was validated for discrimination of benign from cancer nuclei. This score demonstrated field effects in benign epithelial nuclei at varying distance from PCa lesions, and was associated with subsequent PCa detection in negative biopsies. IMPACT: This nuclear score shows promise as a risk predictor among men with negative biopsies and as an intermediate biomarker in Phase II chemoprevention trials. The results also suggest that subvisual disturbances in nuclear structure precede the development of pre-neoplastic lesions.
format Online
Article
Text
id pubmed-3724855
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37248552013-08-06 Development of a Nuclear Morphometric Signature for Prostate Cancer Risk in Negative Biopsies Gann, Peter H. Deaton, Ryan Amatya, Anup Mohnani, Mahesh Rueter, Erika Enk Yang, Yirong Ananthanarayanan, Viju PLoS One Research Article BACKGROUND: Our objective was to develop and validate a multi-feature nuclear score based on image analysis of direct DNA staining, and to test its association with field effects and subsequent detection of prostate cancer (PCa) in benign biopsies. METHODS: Tissue sections from 39 prostatectomies were Feulgen-stained and digitally scanned (400×), providing maps of DNA content per pixel. PCa and benign epithelial nuclei were randomly selected for measurement of 52 basic morphometric features. Logistic regression models discriminating benign from PCa nuclei, and benign from malignant nuclear populations, were built and cross-validated by AUC analysis. Nuclear populations were randomly collected <1 mm or >5 mm from cancer foci, and from cancer-free prostates, HGPIN, and PCa Gleason grade 3–5. Nuclei also were collected from negative biopsy subjects who had a subsequent diagnosis of PCa and age-matched cancer-free controls (20 pairs). RESULTS: A multi-feature nuclear score discriminated cancer from benign cell populations with AUCs of 0.91 and 0.79, respectively, in training and validation sets of patients. In prostatectomy samples, both nuclear- and population-level models revealed cancer-like features in benign nuclei adjacent to PCa, compared to nuclei that were more distant or from PCa-free glands. In negative biopsies, a validated model with 5 variance features yielded significantly higher scores in cases than controls (P = 0.026). CONCLUSIONS: A multifeature nuclear morphometric score, obtained by automated digital analysis, was validated for discrimination of benign from cancer nuclei. This score demonstrated field effects in benign epithelial nuclei at varying distance from PCa lesions, and was associated with subsequent PCa detection in negative biopsies. IMPACT: This nuclear score shows promise as a risk predictor among men with negative biopsies and as an intermediate biomarker in Phase II chemoprevention trials. The results also suggest that subvisual disturbances in nuclear structure precede the development of pre-neoplastic lesions. Public Library of Science 2013-07-26 /pmc/articles/PMC3724855/ /pubmed/23922715 http://dx.doi.org/10.1371/journal.pone.0069457 Text en © 2013 Gann et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Gann, Peter H.
Deaton, Ryan
Amatya, Anup
Mohnani, Mahesh
Rueter, Erika Enk
Yang, Yirong
Ananthanarayanan, Viju
Development of a Nuclear Morphometric Signature for Prostate Cancer Risk in Negative Biopsies
title Development of a Nuclear Morphometric Signature for Prostate Cancer Risk in Negative Biopsies
title_full Development of a Nuclear Morphometric Signature for Prostate Cancer Risk in Negative Biopsies
title_fullStr Development of a Nuclear Morphometric Signature for Prostate Cancer Risk in Negative Biopsies
title_full_unstemmed Development of a Nuclear Morphometric Signature for Prostate Cancer Risk in Negative Biopsies
title_short Development of a Nuclear Morphometric Signature for Prostate Cancer Risk in Negative Biopsies
title_sort development of a nuclear morphometric signature for prostate cancer risk in negative biopsies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724855/
https://www.ncbi.nlm.nih.gov/pubmed/23922715
http://dx.doi.org/10.1371/journal.pone.0069457
work_keys_str_mv AT gannpeterh developmentofanuclearmorphometricsignatureforprostatecancerriskinnegativebiopsies
AT deatonryan developmentofanuclearmorphometricsignatureforprostatecancerriskinnegativebiopsies
AT amatyaanup developmentofanuclearmorphometricsignatureforprostatecancerriskinnegativebiopsies
AT mohnanimahesh developmentofanuclearmorphometricsignatureforprostatecancerriskinnegativebiopsies
AT ruetererikaenk developmentofanuclearmorphometricsignatureforprostatecancerriskinnegativebiopsies
AT yangyirong developmentofanuclearmorphometricsignatureforprostatecancerriskinnegativebiopsies
AT ananthanarayananviju developmentofanuclearmorphometricsignatureforprostatecancerriskinnegativebiopsies